INDICATION

EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis.

No matter the journey, help SECURE A CURE

Life isn’t perfect.
See what outcomes
ONLY EPCLUSA HAS
for chronic HCV patients.1

Cure = SVR12 (HCV RNA <LLOQ 12 weeks after treatment completion).1,2

Discover why EPCLUSA

Efficacy Results

Learn More

Adherence Data

Learn More

DDI Profile

Learn More